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A B S T R A C T
We describe the ﬁrst patient with a left ventricular assist device (LVAD) driveline infection caused by
Mycobacterium chelonae presenting with persistent infection despite conventional antibiotics. Treatment
was successful with surgical debridement, driveline exit relocation, and a 4-month period of antibiotics.
In the case of a culture-negative LVAD driveline infection, non-tuberculous mycobacteria should be
considered. This case illustrates that multidisciplinary collaboration is essential in providing optimal care
for LVAD patients.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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In a selected group of patients with end-stage heart failure, a
left ventricular assist device (LVAD) is implanted. The number of
LVAD implantations is rising rapidly (de By et al., 2018; Kormos
et al., 2019). One of the most common complications is a driveline
infection. The incidence of LVAD-associated infection (including
driveline infection) is around 28% in the ﬁrst 12 months post-
implantation (de By et al., 2018; Kormos et al., 2019). Early
diagnosis and appropriate treatment is important in order to
prevent an ascending infection, including LVAD pump infections,
which are associated with increased morbidity and mortality (de
By et al., 2018; Kormos et al., 2019; Simeon et al., 2017). This report
describes the case of a patient with a rare cause of an LVAD
driveline infection.
Case report
A 56-year-old Caucasian male with a history of ischemic
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).since 2015 as a bridge to transplant, presented at the outpatient
clinic with pain and a purulent discharge at the driveline exit 3.5
years post-LVAD implantation. There was no fever or redness, and
his C-reactive protein (CRP) level was low at 0.6 mg/l. The patient
was treated with oral levoﬂoxacin 500 mg twice daily after a
bacterial culture of the wound ﬂuid was obtained. As a conse-
quence, he was deemed not eligible for heart transplantation at
that time.
Two weeks later, the patient returned to the outpatient clinic
with a persistent purulent discharge from the driveline exit
without systemic symptoms and with negative bacterial cultures.
The patient was admitted and treated with intravenous antibiotics.
Bacterial, mycobacterial, and fungal cultures were obtained and
incubated for a prolonged period of time (14 days) for the
identiﬁcation of potential fastidious and/or slowly growing
microorganisms. An ultrasound was performed, demonstrating a
ﬂuid collection around the driveline over a length of 15 cm.
Subsequently, a positron emission tomography–computed tomog-
raphy (PET-CT) scan was performed to evaluate the extent of the
infection (Akin et al., 2018) and showed uptake in the subcutane-
ous tissue surrounding the LVAD driveline compatible with the
ultrasound ﬁndings (Figure 1A). Since regular microbial cultures
remained negative, the patient was discharged without antibiotics.
After 6 days, routine bacterial cultures became positive (Figure
1B). Matrix-assisted laser desorption/ionization (MALDI) identi-
ﬁed Mycobacterium chelonae, and acid-fast staining showed theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. (A) Transverse PET-CT view showing clear 18F-FDG uptake in the subcutaneous tissue surrounding the driveline. (B) Growth of Mycobacterium chelonae on chocolate
agar. (C) Acid-fast acid staining showing the presence of mycobacteria. (D) Driveline relocation procedure; the asterisk (*) marks the infected part of the LVAD driveline. (E)
Negative pressure wound therapy after driveline relocation.
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tion conﬁrmed the MALDI ﬁndings, showing a banding pattern
ﬁtting Mycobacterium chelonae/Mycobacterium abscessus complex/
Mycobacterium immunogenum. Further molecular identiﬁcation
with partial gene sequencing of the 16S–23S rRNA internal
transcribed spacer (ITS) region conﬁrmed M. chelonae as the cause
of the driveline infection. The patient was readmitted and started
on imipenem 500 mg four times daily intravenously and
clarithromycin 500 mg twice daily orally, based on susceptibility
results. After 2 weeks of adequate antimicrobial treatment,
surgical debridement was performed with relocation of the
driveline exit to the right side of the abdomen. Negative pressure
wound therapy (vacuum-assisted closure) was initiated at the
location of the old, infected exit site (Figure 1D, E).
After surgical exploration, imipenem and clarithromycin were
continued for one additional week, after which clarithromycin was
combined with doxycycline 100 mg twice daily orally. The total
duration of antibiotic therapy was 4 months. To date (8.5 months
after stopping antibiotics), no infection recurrence has occurred and
the patient is considered eligible for heart transplantation again.
Discussion
LVAD-associated infections are serious infections associated
with high morbidity and mortality (de By et al., 2018; Kormos et al.,
2019; Simeon et al., 2017). LVAD-associated infections can be
divided into driveline infections and ascending or pump infections.
Early diagnosis is important in order to initiate appropriate
antimicrobial therapy with or without surgical debridement to
prevent disease progression. Causative pathogens of LVAD-associated infections are mainly Staphylococcus aureus and
coagulase-negative staphylococci, which cause approximately
50% of infections, but Pseudomonas aeruginosa and Enterobacter-
iaceae infections have also been described (Simeon et al., 2017;
Nienaber et al., 2013; Kusne et al., 2017). LVAD infections caused by
non-tuberculous mycobacteria (NTM) are extremely rare. Recently,
Nunez Breton et al. reported two cases of driveline infection caused
by M. abscessus (Nunez Breton et al., 2018). Mycobacterium
chimaera was reported in two patients in the context of a
worldwide outbreak of infected heater cooler units (Balsam
et al., 2017). Here, we describe the ﬁrst patient with an LVAD
driveline infection caused by M. chelonae.
NTM are ubiquitous environmental organisms found in soil,
dust, and water. Together with M. abscessus complex and
Mycobacterium fortuitum, M. chelonae is the most clinically relevant
species within the group of rapidly growing NTM (RGM). RGM are
characterized by the ability to grow on solid culture media within
seven days, as opposed to the slowly growing NTM, which usually
require more than seven days for growth. In general, it is
recommended that cultures are obtained in speciﬁc liquid media
as well as solid media when there is a clinical suspicion of NTM
infection (Grifﬁth et al., 2007). Furthermore, it is recommended
that low temperature settings are used, as for several NTM,
including M. chelonae, the optimal growth temperature is 30 C.
Interestingly, in our case, culture of the pus from the exit site on
routine bacterial medium was positive on day six, while the liquid
and solid cultures on speciﬁc mycobacterial culture media
remained negative. This might be due to the decontamination
procedure, which is routinely performed when non-sterile speci-
mens are prepared for mycobacterial diagnostics. Although this
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microorganisms, it may hamper the detection of NTM and RGM in
particular (Grifﬁth et al., 2007). Therefore, including prolonged
incubation on non-speciﬁc bacterial culture media might increase
the detection rate of NTM, as was the case for our patient. Once a
mycobacterial culture is positive, proper species identiﬁcation is
crucial, since susceptibility and optimal treatment regimens differ
between different NTM and between different RGM. In general,
treatment requires a combination of antibiotic agents based on
susceptibility results for at least four months in the case of skin and
soft tissue infections (Grifﬁth et al., 2007). Our patient was
successfully treated with a 4-month combination antibiotic
regimen, surgical debridement, and driveline relocation. Since
NTM including RGM have the tendency to form bioﬁlms, removing
the foreign material in the case of NTM infections of prosthetic
material seems prudent whenever feasible (Sousa et al., 2015).
Measures to prevent the recurrence of NTM infection could not
be established, as speciﬁc risk factors (e.g., hot tub exposure or
sauna visits) were not identiﬁed. Furthermore, such exposures are
not allowed in this patient population.
In conclusion, in patients with an LVAD driveline infection
unresponsive to conventional antibiotic regimens and with negative
bacterial cultures on non-selective culture media, NTM and RGM in
particular should be considered as a cause. Furthermore, the use of
selective culture media including prolonged incubation in non-
selective culture media at different temperatures might increase the
yield. The combination of prolonged antibiotic therapy and surgical
debridement and driveline relocation seems a prudent approach.
Nevertheless, a multidisciplinary approach should be used in each
case to determine the optimal managementofLVAD-associatedNTM
infections.
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